Based on the evidence, here are 5 key recovery aspects cancer patients should consider after running or walking events:
1. Cool Down with Gentle Stretching
Stretching and range of motion exercises should be performed after exercise when muscles are warm to reduce injury and discomfort.[1] The NCCN guidelines specifically recommend stretching major muscle groups as part of the cool-down period following aerobic exercise sessions.[1] This helps prevent muscle stiffness and supports recovery.
2. Monitor and Manage Fatigue
Cancer-related fatigue is distinct from normal exercise fatigue and requires special attention. Participants should self-monitor fatigue levels and practice energy conservation strategies.[2] Key approaches include:
- Scheduling rest periods at appropriate times without interfering with nighttime sleep quality
- Prioritizing activities and pacing themselves in the days following the event
- Understanding that some fatigue is expected but should gradually improve[3]
If fatigue persists or worsens significantly, participants should consult their healthcare provider, as this may indicate the need for additional evaluation.[2]
3. Stay Hydrated and Maintain Proper Nutrition
While specific hydration protocols weren’t detailed in cancer exercise guidelines, nutrition consultation is recommended as part of comprehensive fatigue management.[2] Participants should:
- Ensure adequate fluid and electrolyte intake, particularly important given that cancer treatments can affect fluid balance[2]
- Maintain adequate caloric intake to support recovery
- Consider consulting with a nutritionist if experiencing treatment-related nutritional challenges
4. Listen to Your Body and Recognize Warning Signs
Cancer patients need to be aware of specific safety considerations that differ from the general population. Important cautions include:[2]
- Bone metastases (increased fracture risk)
- Low platelet counts (thrombocytopenia)
- Anemia
- Recent surgery or active infection
- Persistent or late effects of treatment such as cardiomyopathy
- Fall risk assessment
Participants should avoid pushing through unusual symptoms and should contact their healthcare team if they experience chest pain, severe shortness of breath, dizziness, or other concerning symptoms.
5. Maintain Activity Levels Going Forward
The event should be viewed as part of an ongoing physical activity program rather than an isolated achievement.[1][4] Evidence strongly supports that cancer survivors should:
- Continue with at least 150 minutes of moderate-intensity activity per week (or 75 minutes of vigorous-intensity)[1][4]
- Engage in strength/resistance training 2-3 times per week[1]
- Avoid prolonged sedentary behavior in the days following the event[1]
- Consider joining structured exercise programs designed for cancer survivors if additional support is needed[5]
Physical activity has been shown to improve cardiorespiratory fitness, reduce fatigue, and enhance quality of life both during and after cancer treatment.[6]
References
- Survivorship. National Comprehensive Cancer Network. Updated 2026-04-08.
- Cancer-Related Fatigue. National Comprehensive Cancer Network. Updated 2026-04-10.
- Management of Fatigue in Adult Survivors of Cancer: ASCO-Society for Integrative Oncology Guideline Update. Bower JE, Lacchetti C, Alici Y, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2024;42(20):2456-2487. doi:10.1200/JCO.24.00541.
- American Cancer Society Nutrition and Physical Activity Guideline for Cancer Survivors. Rock CL, Thomson CA, Sullivan KR, et al. CA: A Cancer Journal for Clinicians. 2022;72(3):230-262. doi:10.3322/caac.21719.
- Real-world feasibility and efficacy of a tailored exercise program in patients with cancer.. Avancini A, Borsati A, Adamoli G, et al. Journal of Clinical Oncology. 2026;44(Suppl 16):12040. doi:10.1200/JCO.2026.44.16_suppl.12040.
- Exercise, Diet, and Weight Management During Cancer Treatment: ASCO Guideline. Ligibel JA, Bohlke K, May AM, et al. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2022;40(22):2491-2507. doi:10.1200/JCO.22.00687.




